Replies to post #110252 on Amarantus Bioscience Holdings Inc (AMBS)

[joboggi]

Any time I mention that, I get hounded down. Yet, it continues to be true. Only AMBS is excited about their "new" actually old test.

In its short life, it will only be used in a few studies, at most. Then it will be entirely replaced by other tests. That will be the extent of it. We are talking a few hundred tests, to a few thousand, at most, and I am being generous at that.

Also, the ramifications of getting a test when there is no treatment are discussed, and remain accurate as they were 30 years ago.

[brharris]

As always many looking to put the cart before the horse. AMBS has stated when they would start publishing articles on LymPro and that time has not come yet. Full LP 002 result and launch in RUO market will begin in the next couple weeks.

The univariate numbers in the 70/80 range suggest that multivariate numbers will likely be in the 90s.

[leslunier]

Alapis, after reading that article I sent the author Megan an e-mail telling her about Lympro. She responded to me an stated that she thought Lympro was a test to determine if a patient has AD after symptoms occur. I told her to go to AMBS web site and see where we are. She thanked me and said she would do that. Word has to get out if this company is going to survive. When an article doesn't mention AMBS we need to make the authors aware of our company instead of complaining we weren't mentioned.